Sökning: onr:"swepub:oai:DiVA.org:uu-325671" > The EU-AIMS Longitu...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 06813naa a2201213 4500 | |
001 | oai:DiVA.org:uu-325671 | |
003 | SwePub | |
008 | 170627s2017 | |||||||||||000 ||eng| | |
009 | oai:prod.swepub.kib.ki.se:136090654 | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3256712 URI |
024 | 7 | a https://doi.org/10.1186/s13229-017-0146-82 DOI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1360906542 URI |
040 | a (SwePub)uud (SwePub)ki | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Loth, Eva4 aut |
245 | 1 0 | a The EU-AIMS Longitudinal European Autism Project (LEAP) :b design and methodologies to identify and validate stratification biomarkers for autism spectrum disorders. |
264 | c 2017-06-23 | |
264 | 1 | b Springer Science and Business Media LLC,c 2017 |
338 | a electronic2 rdacarrier | |
520 | a BACKGROUND: The tremendous clinical and aetiological diversity among individuals with autism spectrum disorder (ASD) has been a major obstacle to the development of new treatments, as many may only be effective in particular subgroups. Precision medicine approaches aim to overcome this challenge by combining pathophysiologically based treatments with stratification biomarkers that predict which treatment may be most beneficial for particular individuals. However, so far, we have no single validated stratification biomarker for ASD. This may be due to the fact that most research studies primarily have focused on the identification of mean case-control differences, rather than within-group variability, and included small samples that were underpowered for stratification approaches. The EU-AIMS Longitudinal European Autism Project (LEAP) is to date the largest multi-centre, multi-disciplinary observational study worldwide that aims to identify and validate stratification biomarkers for ASD.METHODS: LEAP includes 437 children and adults with ASD and 300 individuals with typical development or mild intellectual disability. Using an accelerated longitudinal design, each participant is comprehensively characterised in terms of clinical symptoms, comorbidities, functional outcomes, neurocognitive profile, brain structure and function, biochemical markers and genomics. In addition, 51 twin-pairs (of which 36 had one sibling with ASD) are included to identify genetic and environmental factors in phenotypic variability.RESULTS: Here, we describe the demographic characteristics of the cohort, planned analytic stratification approaches, criteria and steps to validate candidate stratification markers, pre-registration procedures to increase transparency, standardisation and data robustness across all analyses, and share some 'lessons learnt'. A clinical characterisation of the cohort is given in the companion paper (Charman et al., accepted).CONCLUSION: We expect that LEAP will enable us to confirm, reject and refine current hypotheses of neurocognitive/neurobiological abnormalities, identify biologically and clinically meaningful ASD subgroups, and help us map phenotypic heterogeneity to different aetiologies. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Psykiatri0 (SwePub)302152 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Psychiatry0 (SwePub)302152 hsv//eng |
653 | a Biomarkers | |
653 | a Cognition | |
653 | a EEG | |
653 | a Eye-tracking | |
653 | a Genetics | |
653 | a MRI | |
653 | a Neuroimaging | |
700 | 1 | a Charman, Tony4 aut |
700 | 1 | a Mason, Luke4 aut |
700 | 1 | a Tillmann, Julian4 aut |
700 | 1 | a Jones, Emily J H4 aut |
700 | 1 | a Wooldridge, Caroline4 aut |
700 | 1 | a Ahmad, Jumana4 aut |
700 | 1 | a Auyeung, Bonnie4 aut |
700 | 1 | a Brogna, Claudia4 aut |
700 | 1 | a Ambrosino, Sara4 aut |
700 | 1 | a Banaschewski, Tobias4 aut |
700 | 1 | a Baron-Cohen, Simon4 aut |
700 | 1 | a Baumeister, Sarah4 aut |
700 | 1 | a Beckmann, Christian4 aut |
700 | 1 | a Brammer, Michael4 aut |
700 | 1 | a Brandeis, Daniel4 aut |
700 | 1 | a Bölte, Svenu Karolinska Institutet4 aut |
700 | 1 | a Bourgeron, Thomas4 aut |
700 | 1 | a Bours, Carsten4 aut |
700 | 1 | a de Bruijn, Yvette4 aut |
700 | 1 | a Chakrabarti, Bhismadev4 aut |
700 | 1 | a Crawley, Daisy4 aut |
700 | 1 | a Cornelissen, Ineke4 aut |
700 | 1 | a Acqua, Flavio Dell'4 aut |
700 | 1 | a Dumas, Guillaume4 aut |
700 | 1 | a Durston, Sarah4 aut |
700 | 1 | a Ecker, Christine4 aut |
700 | 1 | a Faulkner, Jessica4 aut |
700 | 1 | a Frouin, Vincent4 aut |
700 | 1 | a Garces, Pilar4 aut |
700 | 1 | a Goyard, David4 aut |
700 | 1 | a Hayward, Hannah4 aut |
700 | 1 | a Ham, Lindsay M4 aut |
700 | 1 | a Hipp, Joerg4 aut |
700 | 1 | a Holt, Rosemary J4 aut |
700 | 1 | a Johnson, Mark H4 aut |
700 | 1 | a Isaksson, Johanu Karolinska Institutet,Uppsala universitet,Barn- och ungdomspsykiatri,Karolinska Inst KIND, Ctr Neurodev Disorders, Stockholm, Sweden4 aut0 (Swepub:uu)johis856 |
700 | 1 | a Kundu, Prantik4 aut |
700 | 1 | a Lai, Meng-Chuan4 aut |
700 | 1 | a D'ardhuy, Xavier Liogier4 aut |
700 | 1 | a Lombardo, Michael V4 aut |
700 | 1 | a Lythgoe, David J4 aut |
700 | 1 | a Mandl, René4 aut |
700 | 1 | a Meyer-Lindenberg, Andreas4 aut |
700 | 1 | a Moessnang, Carolin4 aut |
700 | 1 | a Mueller, Nico4 aut |
700 | 1 | a O'Dwyer, Laurence4 aut |
700 | 1 | a Oldehinkel, Marianne4 aut |
700 | 1 | a Oranje, Bob4 aut |
700 | 1 | a Pandina, Gahan4 aut |
700 | 1 | a Persico, Antonio M4 aut |
700 | 1 | a Ruigrok, Amber N V4 aut |
700 | 1 | a Ruggeri, Barbara4 aut |
700 | 1 | a Sabet, Jessica4 aut |
700 | 1 | a Sacco, Roberto4 aut |
700 | 1 | a Cáceres, Antonia San José4 aut |
700 | 1 | a Simonoff, Emily4 aut |
700 | 1 | a Toro, Roberto4 aut |
700 | 1 | a Tost, Heike4 aut |
700 | 1 | a Waldman, Jack4 aut |
700 | 1 | a Williams, Steve C R4 aut |
700 | 1 | a Zwiers, Marcel P4 aut |
700 | 1 | a Spooren, Will4 aut |
700 | 1 | a Murphy, Declan G M4 aut |
700 | 1 | a Buitelaar, Jan K4 aut |
710 | 2 | a Karolinska Institutetb Barn- och ungdomspsykiatri4 org |
773 | 0 | t Molecular Autismd : Springer Science and Business Media LLCg 8q 8x 2040-2392 |
856 | 4 | u https://doi.org/10.1186/s13229-017-0146-8y Fulltext |
856 | 4 | u https://uu.diva-portal.org/smash/get/diva2:1115617/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print |
856 | 4 | u https://molecularautism.biomedcentral.com/track/pdf/10.1186/s13229-017-0146-8 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-325671 |
856 | 4 8 | u https://doi.org/10.1186/s13229-017-0146-8 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:136090654 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy